Merus

Clinical-stage oncology company developing Biclonics® bispecific antibody therapeutics. Please see our Community Guidelines:

[Merus @MerusNV]

Based on the opinions of our employees, we’re a 2022 World Class Workplace. This label is awarded by Effectory to celebrate organizations who are dedicated to their people. Thanks to everyone at Merus who makes our organization a great place to work.
#CloseInOnCancer

[Merus @MerusNV]

We look forward to sharing robust updated interim phase 2 data on petosemtamab plus pembrolizumab as first line treatment for PD-L1+ r/m #HNSCC, on the entire 45 patient data set, on an upcoming investor conference call on May 22 at 5:30 p.m. ET and in our presentation at #ASCO25. We continue to believe petosemtamab has the potential to be a first and best in class, practice-changing medicine for the treatment of r/m #HNSCC. #CloseInOnCancer

https://t.co/rKqhVaCDmq

[Merus @MerusNV]

In May 2024 and February 2025, the U.S. FDA granted Breakthrough Therapy designations to petosemtamab: as monotherapy in 2L+ r/m #HNSCC, and in combination with pembrolizumab in 1L PD-L1+ r/m #HNSCC, respectively. We are dedicated to advancing petosemtamab as a potential new therapy for the treatment of r/m #HNSCC.
#ClosingInOnCancer

[Merus @MerusNV]

Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN2 trial has over 93 sites open across North and South America, Europe, Asia, and Australia. For more information,
visit https://t.co/oCRXQ6YCno
NCT06496178. #CloseInOnCancer

[Merus @MerusNV]

Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN1 trial has over 105 sites open across North and South America, Europe, Asia, and Australia. For more information,
visit https://t.co/oCRXQ6YCno
NCT06525220. #CloseInOnCancer

[Merus @MerusNV]

At Merus, every day, we bring a sense of urgency and a passion to help patients. In April we recognize the patients with recurrent/metastatic #HNSCC. We remain steadfast in our commitment to advance our lead cancer drug candidate petosemtamab as a potential new treatment for patients.
#CloseInOnCancer

[Merus @MerusNV]

Bill Lundberg, MD, Merus’ CEO, will present today at Citi’s 2025 Virtual Oncology Leadership Summit. The presentation will be available on our Investors page and for a limited time thereafter.
#CloseInOnCancer

[Merus @MerusNV]

We hope to see you at #ESMOAsia24 where clinical trial data on petosemtamab as 2L+ treatment of recurrent/metastatic #HNSCC will be presented.
#ClosingInOnCancer
https://t.co/f9rkn4Un5J

[Merus @MerusNV]

Attending AMP2024? Visit us at Booth 706. Did you know that NRG1+ tumors may have a higher rate of metastasis compared with KRAS+ tumors? Go to https://t.co/tOIPV4rLsR and find out more about the metastatic potential of NRG1+ tumors. #AMP2024 #PrecisionOncology #FindTheFusions #PrecisionMedicine

[Merus @MerusNV]

Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat today at the Stifel 2024 Healthcare Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer

[Merus @MerusNV]

November is #LungCancerAwareness Month—a time to honor and support those impacted by the leading cause of cancer death worldwide.
#CloseInOnCancer

[Merus @MerusNV]

Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer

[Merus @MerusNV]

November is #PancreaticCancerAwareness Month, a time to support those battling one of the most challenging cancers to detect and treat.
#CloseInOnCancer

[Merus @MerusNV]

The Merus team recently celebrated the end of summer and welcomed the start of the fall season with a fun and highly competitive outing.
#Team
#CloseInOnCancer

[Merus @MerusNV]

Please join us in welcoming Audrey as our Chief People Officer. Audrey has more than 25 years of experience attracting, developing, and retaining top talent in the pharmaceutical and biotechnology industries. We're excited to have her on the team as we #CloseInOnCancer.

[Merus @MerusNV]

Wishing everyone a safe and happy Halloween!
#CloseInOnCancer

[Merus @MerusNV]

We are excited for Adair to join the Merus team as our Internal Communications Officer. Welcome aboard!
#CloseInOnCancer

[Merus @MerusNV]

What is the optimal way to detect pathogenic gene fusions like NRG1?  Benjamin Weinberg, MD, highlights the advantages of RNA-based next generation sequencing and how it can capture what other tests might miss. Watch the video at https://t.co/GRKKqHO7IV #PrecisionOncology #FindTheFusions #PrecisionMedicine

[Merus @MerusNV]

Over the summer, we profiled some of our team members. You can find their stories, along with our current vacancies on our careers page: https://t.co/dptxvhM0Lf

#CloseInOnCancer
#JoinTheMerusMission

[Merus @MerusNV]

We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab 1L r/m #HNSCC #CloseInOnCancer

[Merus @MerusNV]

We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab in 1L PD-L1+ r/m  #HNSCC #CloseInOnCancer
https://t.co/Bg9P31qOqU